TOTumutolova O.M.

Tumutolova O.M.

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tumutolova O.M. has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PHARMACOLOGICAL ACTIVITY OF LHT-17-19 IN CULTURES OF EGFR-EXPRESSING EPITHELIAL TUMORS

    by Kudryavtsev M.YU., Tumutolova O.N., Deryabina O.N., Epishkina A.A., Vavilova O.S., Gilevskaya Yu.S., Blinova E.V.

    . In the study, the pharmacological activity of the pyridine derivative LHT-17-19 was studied in relation to the culture of pancreatic cancer cells PANC-1 and the culture of bladder cancer cells HT-29 expressing the epidermal growth factor receptor. The cultures were obtained from the library of tumor strains of the Moscow Research Institute of Oncology. P.A. Herzen - a separate structural subdivision of the Federal State Budgetary Institution "NMITs Radiology" of the Ministry of Health of Russia. LHT-17-19 was synthesized in the Department of Chemistry, Technology of Synthetic Medicines and Analytical Control of JSC VNTs BAV (Russia). LHT-17-19 and the reference drug "Doxorubicin" 50 mg each were added to the cultivation medium in the concentration range from 10-8 to 10-v. Compounds LHT-17-19 were shown to be able to induce death and suppress the growth of pancreatic cancer squamous culture (PANC-1) and bladder (HT-29) tumor cells expressing EGFR over a wide range of concentrations. So for pancreatic cancer (PANC-1), the effective inhibitory concentration for the compound LHT-17-19 was 1.3 × 10-7 M, while for the reference substance doxorubicin it was 6.0 × 10-5 M. bubble (NT-29) - 2.4 × 10-7 M and 5.2 × 10-4 M, respectively.


  • PHARMACOLOGICAL ACTIVITY OF AN AMINOCHROMENE DERIVATIVE IN THE TREATMENT OF BREAST CANCER (EXPERIMENTAL STUDY)

    by Deryabina O.N., Blinova Е.в., Samyshina E.A., Demura T.A., Epishkina A.A., Dudina M.O., Tumutolova O.M.

    We studied an antitumor effect of a compound of 4-aminochromene derivatives (AX-554) in the tumor system of breast cancer Ca-755. We used C57Bl / 6 mice, which were subcutaneously injected with a suspension of Ca-755 tumor cells into the right axillary region in the amount of 1×106 cells in 199 solution. AX-554 was administered intragastrically through a tube once on the 48 hours after tumor transplantation, in comparison with reference antitumor drugs with proven antitumor activity, which were used as doxorubicin, paclitaxel. The antitumor activity was judged by the survival rate of animals, the size and morphology of the tumor node. It was shown that the 4-aminochromene derivative AX-554 increases the survival rate of animals with breast cancer by 30% compared with the control group and by 10% with the group receiving doxorubicin. with control. In the study of tumor sections stained with hemotoxylin and eosin in animals treated with AX-554, there were single tumor cells in a state of severe dystrophy, the necrosis zone was 90%, which indicates drug pathomorphosis of the 3rd degree. In animals treated with doxorubicin, atypical cells in the center of the tumor node retained their structure, in the periphery - cells in a state of dystrophy, foci of necrosis accounted for 60%. The morphological picture of the tumor in animals treated with paclitaxel was a drug pathomorphosis of the 2nd degree.

  • EPIDEMIOLOGICAL CHARACTERISTICS OF BREAST CANCER IN THE REPUBLIC OF MORDOVIA

    by Deryabina O.N., Blinova E.V., Dagar E.A., Tumutolova O.M.

    The article analyzes the main epidemiological characteristics of breast cancer in the Republic of Mordovia in comparison with the Russian Federation. Based on the official accounting and reporting documentation for 2011-2019. the territorial and age-specific features of the incidence were determined, the structure of pathomorphological forms of breast cancer was assessed, the weighted average cost of providing specialized medical care for breast neoplasms in a hospital in the Republic of Mordovia was calculated. It has been shown that the incidence of breast cancer in the Republic of Mordovia for 2011-2019 increased, which corresponds to the all-Russian laws: 6.11 per 100 thousand women in the age group of women 25-29 years old to 213.14 in the age group 60-64 years. Infiltrating ductal carcinoma prevailed in the structure of the pathomorphological form of breast cancer among the inhabitants of the Republic - 58.8%. It has been shown that the cost of providing specialized hospital care for stage III breast cancer is 8 times higher than for stages I-II of breast cancer. Thus, the analysis showed that breast cancer is a serious medical and social problem, and effective treatment of the disease requires costly treatment in a specialized hospital, and the cost of drug therapy for the disease increases significantly at advanced stages.

  • Open Access

    MONITORING OF HIV-INFECTION IN THE REPUBLIC OF MORDOVIA (UPDATED 2015)

    by National Research Mordovia State University, Dmitriy S. Blinov, Mariya G. Laseyeva, Natalya N. Chernova, Oksana P. Balykova, Lyudmila I. Kitayeva, Oksana M. Tumutolova

    Официальный сайт журнала "Вестник Мордовского университета"